| Literature DB >> 26402026 |
Maroya Spalding Walters, Paula Eggers, Valerie Albrecht, Tatiana Travis, David Lonsway, Greg Hovan, Debra Taylor, Kamile Rasheed, Brandi Limbago, Alexander Kallen.
Abstract
Vancomycin-resistant Staphylococcus aureus (VRSA) is a rare, multidrug-resistant bacterium of public health concern that emerged in the United States in 2002. VRSA (S. aureus with vancomycin minimum inhibitory concentration [MIC] ≥16 μg/mL) arises when vancomycin resistance genes (e.g., the vanA operon, which codes for enzymes that result in modification or elimination of the vancomycin binding site) from vancomycin-resistant enterococci (VRE) are transferred to S. aureus (1). To date, all VRSA strains have arisen from methicillin-resistant S. aureus (MRSA). The fourteenth VRSA isolate (VRSA 14) identified in the United States was reported to CDC in February 2015.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26402026 DOI: 10.15585/mmwr.mm6437a6
Source DB: PubMed Journal: MMWR Morb Mortal Wkly Rep ISSN: 0149-2195 Impact factor: 17.586